« Back
Home /
Tavilermide

Tavilermide

Item no.	HY-17622-25mg
Manufacturer	MedChem Express
CASRN	263251-78-1
Amount	25 mg
Quantity options	100 mg 10 mMx1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Oncology Neuroscience Molecular Targets for Neuroscience Targets for Rodent Neurosciences Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer
Type	Inhibitors
Specific against	other
Purity	99.57
Citations	[1]Meerovitch K, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013;7:1275-85.
Smiles	O=C(O)CC[C@H](N1)C(N[C@@H](CCCCN)C(N[C@H](C(NCC(O)=O)=O)CCOC2=CC=C([N+]([O-])=O)C=C2C1=O)=O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	MIM-D3
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Trk Receptor
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	580.54
Product Description	Tavilermide is a selective, partial agonist of TrkA, or a nerve growth factor (NGF) mimetic.
Manufacturer - Research Area	Inflammation/Immunology
Solubility	H2O: 2 mg/mL (ultrasonic)\|NH4OH: 50 mg/mL (ultrasonic; adjust pH to 10 with NH4OH)
Manufacturer - Pathway	Neuronal Signaling; Protein Tyrosine Kinase/RTK
Isoform	TrkA
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-17622-25mg-safety-datasheet.pdf